TG THERAPEUTICS, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
TG THERAPEUTICS, INC. (TGTX) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $40.45 million as of 2023-06-30, per its 10-Q filed 2023-08-04.
Discontinued › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2023-08-04
- 2023-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $40.45M.
- 2023-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $27.43M.
- 2022-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $58.59M.
- 2022-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $100.48M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2023-06-30 | $40.45M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $27.43M 10-Q · filed 2023-08-04 | |
| 2022-12-31 | $58.59M 10-Q · filed 2023-08-04 | |
| 2022-09-30 | $100.48M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $129.03M 10-Q · filed 2023-08-04 | |
| 2022-03-31 | $170.39M 10-Q · filed 2023-08-04 | |
| 2021-12-31 | $237.15M 10-Q · filed 2023-08-04 | |
| 2021-09-30 | $311.52M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $383.13M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $445.29M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $519.35M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $170.66M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $194.23M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | -$1.35M 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $38.62M 10-K · filed 2023-03-01 | |
| 2019-09-30 | -$25.79M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $13.21M 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $19.25M 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $24.04M 10-K · filed 2022-03-01 | |
| 2018-09-30 | $71.74M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $101.38M 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $85.23M 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $66.99M 10-K · filed 2021-03-01 | $66.99M 10-K · filed 2018-03-15 |
| 2017-09-30 | $79.55M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $77.98M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $101.04M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $35.87M 10-K · filed 2020-03-02 | $35.87M 10-K · filed 2017-03-16 |
| 2016-09-30 | $56.75M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $78.70M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $89.45M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $101.57M 10-K · filed 2019-03-01 | $101.57M 10-K · filed 2016-03-15 |
| 2015-09-30 | $116.31M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $112.95M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $106.23M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $80.10M 10-K · filed 2018-03-15 | |
| 2014-09-30 | $67.08M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $52.10M 10-Q · filed 2014-07-24 | |
| 2014-03-31 | $54.43M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $40.05M 10-K · filed 2017-03-16 | |
| 2013-09-30 | $44.64M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $10.28M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $14.70M 10-Q · filed 2013-05-14 | |
| 2012-12-31 | $15.55M 10-K · filed 2016-03-15 | |
| 2012-09-30 | $17.89M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $19.79M 10-Q/A · filed 2012-09-07 | |
| 2012-03-31 | $21.19M 10-Q · filed 2012-05-14 | |
| 2011-12-31 | $9.64M 10-K · filed 2014-03-07 | |
| 2010-12-31 | $0.00 8-K/A · filed 2012-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |